Use of atypical antipsychotics in nursing homes and pharmaceutical marketing

Journal of the American Geriatrics Society

Volumn 63, Issue 2, 2015, Pages 297-301

  Pimentel, Camilla B ^a   Donovan, Jennifer L ^b,c   Field, Terry S ^c   Gurwitz, Jerry H ^c   Harrold, Leslie R ^c   Kanaan, Abir O ^b,c   Lemay, Celeste A ^c   Mazor, Kathleen M ^c   Tjia, Jennifer ^c   Briesacher, Becky A ^c  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

atypical antipsychotics; nursing homes; pharmaceutical marketing

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT;

ADMINISTRATIVE PERSONNEL; ARTICLE; CROSS-SECTIONAL STUDY; DRUG MARKETING; DRUG USE; HUMAN; LEADERSHIP; MEDICAL EDUCATION; NURSING HOME; PRESCRIPTION; SEMI STRUCTURED INTERVIEW; CLINICAL PRACTICE; CLUSTER ANALYSIS; CONTROLLED STUDY; DRUG UTILIZATION; FINANCIAL MANAGEMENT; HEALTH CARE FACILITY; HEALTH CARE QUALITY; RANDOMIZED CONTROLLED TRIAL; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ANTIPSYCHOTIC AGENTS; CLUSTER ANALYSIS; CONNECTICUT; CROSS-SECTIONAL STUDIES; DRUG UTILIZATION; HEALTH FACILITY SIZE; HUMANS; MARKETING OF HEALTH SERVICES; NURSING HOMES; PRACTICE PATTERNS, PHYSICIANS'; QUALITY OF HEALTH CARE;

EID: 84923225194     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/jgs.13180     Document Type: Article

References (28)

1. U.S. Department of Health and Human Services. Medicare Atypical Antipsychotic Drug Claims for Elderly Nursing Home Residents (OIG Publication No. OEI-07-08- 00150) [on-line]. Available at http://oig.hhs.gov/oei/reports/oei-07&08&00150.pdf Accessed June 29, 2012.
2. Dorsey ER, Rabbani A, Gallagher SA, et al. Impact of FDA black box advisory on antipsychotic medication use. Arch Intern Med 2010; 170: 96-103.
3. Gill SS, Bronskill SE, Normand SL, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 2007; 146: 775-786.
4. Briesacher BA, Tjia J, Field T, et al. Antipsychotic use among nursing home residents. JAMA 2013; 309: 440-442.
5. Gellad WF, Aspinall SL, Handler SM, et al. Use of antipsychotics among older residents in VA nursing homes. Med Care 2012; 50: 954-960.
6. Chen Y, Briesacher BA, Field TS, et al. Unexplained variation across US nursing homes in antipsychotic prescribing rates. Arch Intern Med 2010; 170: 89-95.
7. Kamble P, Sherer J, Chen H, et al. Off-label use of second-generation antipsychotic agents among elderly nursing home residents. Psychiatr Serv 2010; 61: 130-136.
8. Castle NG, Engberg J,. Staff turnover and quality of care in nursing homes. Med Care 2005; 43: 616-626.
9. Hughes CM, Lapane KL, Mor V,. Influence of facility characteristics on use of antipsychotic medications in nursing homes. Med Care 2000; 38: 1164-1173.
10. Henry J, Kaiser Family Foundation. National survey of physicians, part II: Doctors and prescription drugs [on-line]. Available at http://www.kff.org/rxdrugs/loader.cfm?url=/commonspot/security/getfile.cfm&pageid=13965 Accessed June 29, 2012.
11. Tjia J, Briesacher BA, Soumerai SB, et al. Medicare beneficiaries and free prescription drug samples: A national survey. J Gen Intern Med 2008; 23: 709-714.
12. Adair RF, Holmgren LR,. Do drug samples influence resident prescribing behavior? A randomized trial Am J Med 2005; 118: 881-884.
13. Orlowski JP, Wateska L,. The effects of pharmaceutical firm enticements on physician prescribing patterns. There's no such thing as a free lunch. Chest 1992; 102: 270-273.
14. Wengel SP, Magnuson T, Roccaforte WH, et al. The pharmaceutical industry in the nursing home: No such thing as a free lunch. Am J Geriatr Psychiatry 2003; 11: 111.
15. Tjia J, Field T, Lemay C, et al. Antipsychotic use in nursing homes varies by psychiatric consultant. Med Care 2014; 52: 267-271.
16. Lemay CA, Mazor KM, Field TS, et al. Knowledge of and perceived need for evidence-based education about antipsychotic medications among nursing home leadership and staff. J Am Med Dir Assoc 2013; 14: 895-900.
17. Briesacher BA, Soumerai SB, Field TS, et al. Nursing home residents and enrollment in Medicare Part D. J Am Geriatr Soc 2009; 57: 1902-1907.
18. Fogel ML,. Survey of pharmaceutical promotion in a family medicine training program. Can Fam Physician 1989; 35: 1603-1605.
19. Shaughnessy AF,. Drug promotion in a family medicine training center. JAMA 1988; 260: 926.
20. Tjia J, Gurwitz JH, Briesacher BA,. Challenge of changing nursing home prescribing culture. Am J Geriatr Pharmacother 2012; 10: 37-46.
21. Campbell EG, Gruen RL, Mountford J, et al. A national survey of physician-industry relationships. N Engl J Med 2007; 356: 1742-1750.
22. Brody H,. The company we keep: Why physicians should refuse to see pharmaceutical representatives. Ann Fam Med 2005; 3: 82-85.
23. Studdert DM, Mello MM, Brennan TA,. Financial conflicts of interest in physicians' relationships with the pharmaceutical industry-self-regulation in the shadow of federal prosecution. N Engl J Med 2004; 351: 1891-1900.
24. Wazana A,. Physicians and the pharmaceutical industry: Is a gift ever just a gift? JAMA 2000; 283: 373-380.
25. National Conference on State Legislatures. Marketing and Direct-to-Consumer Advertising (DTCA) of Pharmaceuticals [on-line]. Available at http://www.ncsl.org/research/health/marketing-and-advertising-of-pharmaceuticals.aspx Accessed February 22, 2014.
26. Chimonas S, Rozario NM, Rothman DJ,. Show us the money: Lessons in transparency from state pharmaceutical marketing disclosure laws. Health Serv Res 2010; 45: 98-114.
27. U.S. Centers for Medicare and Medicaid Services. Medicare, Medicaid, Children's Health Insurance Programs; transparency reports and reports of physician ownership or investment interests. Final rule. Fed Regist 2013; 78: 9457-9528.
28. Partnership to Improve Dementia Care in Nursing Homes. Antipsychotic drug use in nursing homes trend update [on-line]. Available at http://www.amda.com/advocacy/AP-package-070513.pdf Accessed January 8, 2014.